AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Zellweger Syndrome

Recent research efforts aimed at curing Zellweger Syndrome.

Last updated

Zellweger Syndrome

Overview

Zellweger syndrome is the most severe end of the Zellweger spectrum disorder (ZSD), a group of inherited conditions caused by harmful variants in PEX genes. These genes are needed to build and maintain peroxisomes—small cell structures that help process particular fats and make or modify important molecules. When peroxisomes do not work, toxic fats and bile-acid intermediates can accumulate and essential lipids can be deficient, affecting the brain, liver, eyes, ears, kidneys, bones, and adrenal glands. ZSD is inherited in an autosomal-recessive pattern and ranges from severe newborn-onset disease to milder, progressive childhood or adult disease. GeneReviews: Zellweger Spectrum Disorder

Classic Zellweger syndrome usually presents in infancy with severe low muscle tone, feeding and breathing difficulties, seizures, liver dysfunction, and major developmental impairment; prognosis is often poor in the most severe group. A 2022 analysis found death by age two in 93% of reported severe cases, whereas survival was substantially longer in intermediate and mild forms. Severity in Zellweger Spectrum Disorder Current care is supportive and multidisciplinary: nutrition and feeding support, seizure treatment, hearing and vision services, monitoring and treatment of liver, adrenal, kidney, and bone complications, and selective use of cholic acid for bile-acid abnormalities. GeneReviews: Zellweger Spectrum Disorder

Scope of Recent Research (2020–present)

Research activity has been modest but has become notably more cure-oriented since 2020. The central questions are whether restoring peroxisome function can prevent irreversible injury, which organs must be reached—especially liver, brain, and retina—and whether treatment can be tailored to specific PEX variants. The field remains early: the strongest curative evidence is currently in mouse models and patient-derived cells, not people, but a 2026 base-editing study provided the first especially compelling evidence that directly correcting a common PEX1 mutation can reverse major disease features in vivo. Base editing in a ZSD mouse model

Major Breakthroughs and Emerging Therapies

The most important recent advance is precision gene editing for the common PEX1 p.Gly843Asp variant. In 2026, investigators used an adenine base editor—a molecular tool designed to change one DNA letter into another—to correct the equivalent disease-causing mutation in Pex1 mice. Intravenous delivery using dual adeno-associated virus 9 (AAV9) vectors corrected as much as 60% of mutant alleles in bulk liver, restored peroxisome-associated metabolic function, reduced harmful very-long-chain and branched-chain fatty acids and toxic C27 bile-acid intermediates, improved liver pathology and growth, and showed minimal detected off-target editing in the reported assays. The same editor corrected more than 80% of target alleles in patient-derived fibroblasts. Base editing in a ZSD mouse model

The same study also tested non-viral lipid nanoparticles (LNPs), which carry editor messenger RNA rather than permanently supplying editor DNA through a virus. LNP delivery corrected the mutant allele in 27% of bulk liver cells in four-week-old mice, establishing a potentially repeat-dosable alternative to AAV delivery. However, both approaches primarily reached the liver; systemic AAV9 administration produced very low editing in mouse cortex, cerebellum, and retina. This is a major limitation because neurological and retinal disease are central causes of disability in ZSD. Base editing in a ZSD mouse model

Small-molecule approaches remain relevant for people with residual-function variants, particularly PEX1 p.Gly843Asp, but are far less advanced than gene editing. A 2021 high-throughput drug screen found that S-nitrosoglutathione (GSNO), a nitric-oxide donor, increased peroxisome number and function in patient fibroblasts and improved survival in a humanized fruit-fly model carrying the corresponding PEX1 variant. This is not a cure and has not established clinical benefit in ZSD, but it supports the concept that some mutant PEX1 proteins can be stabilized or functionally rescued. GSNO rescues PEX1G843D models

Cholic acid is the principal disease-directed medical treatment currently used in selected patients with abnormal bile-acid synthesis, but it does not correct the underlying genetic defect or reverse neurological disease. In a Phase 3 continuation study published in 2020, participants with inborn errors of bile-acid synthesis, including 12 people with ZSD, showed improvements in urinary bile acids and growth measures in the overall cohort; liver enzymes tended to improve in treatment-naïve participants. Phase 3 cholic-acid continuation study This therapy is best viewed as organ-focused metabolic management rather than a curative strategy.

Clinical Trials and Experimental Approaches

No human trial of PEX gene replacement, gene editing, RNA therapy, or cell therapy for ZSD was identified among the recent ZSD-specific studies reviewed here. The leading curative candidate—the PEX1 base-editing program—remains preclinical in mice and patient cells. Base editing in a ZSD mouse model The recently reported Phase 3 cholic-acid continuation trial, NCT01438411, was completed and is listed under Mirum Pharmaceuticals in current registry-derived trial records; it enrolled 53 people with bile-acid synthesis disorders, including 12 with ZSD, and tested oral cholic acid at 10–15 mg/kg/day. Phase 3 cholic-acid continuation study NCT01438411 trial record

A key active study is not therapeutic but is important for making future treatment trials possible. The recruiting ZSDvision study, NCT06190626, is a longitudinal natural-history study of retinal disease sponsored by the McGill University Health Centre/Research Institute; it is designed to define progression and clinically meaningful vision outcomes. ZSDvision natural-history study This work addresses a major trial-design gap because retinal degeneration is common in ZSD, while robust and practical endpoints for measuring change have been limited. Ophthalmic natural-history study

Methodologies and Scientific Approaches

Researchers are combining genotype-specific models with measurements of peroxisome activity. The 2026 editing work used a Pex1 p.Gly844Asp mouse, the counterpart of the human PEX1 p.Gly843Asp allele, alongside patient-derived skin fibroblasts. Researchers measured DNA correction, peroxisomal proteins, liver histology, growth, transcriptomes, and circulating and tissue lipid metabolites to determine whether editing repaired both the mutation and the disease biology. Base editing in a ZSD mouse model

Biomarker development is equally important. Untargeted plasma metabolomics in people with intermediate and mild ZSD identified elevated pipecolic acid and long-chain lysophosphatidylcholines, as well as unexpectedly reduced sphingomyelin species, expanding the potential markers available for diagnosis and for future trials. Metabolomic biomarkers in ZSD Natural-history studies are also defining organ-specific outcome measures: a 2023 retinal study documented progressive visual loss and found that repeated electroretinography alone was not a useful marker of progression, supporting use of multiple structural and functional eye assessments. Ophthalmic natural-history study

Leading Institutions and Funding

The 2026 base-editing collaboration brought together the Broad Institute of MIT and Harvard, Harvard University, the Jackson Laboratory Rare Disease Translational Center, the University of Southern California, the University of Pittsburgh, McGill University, and other partners. The study reports support from multiple National Institutes of Health programs, including U54 OD020351, RM1 HG009490, R35 GM118062, U01 AI142756, R24 OD030033, and U42 OD010921, as well as a Howard Hughes Medical Institute investigatorship. Base editing in a ZSD mouse model

McGill’s ZSD program, led through the McGill University Health Centre/Research Institute, is also central to the field through its prospective retinal natural-history study. ZSDvision natural-history study Cincinnati Children’s Hospital Medical Center and the University of Cincinnati have remained important in bile-acid therapy research, including the Phase 3 cholic-acid continuation study. Phase 3 cholic-acid continuation study

Strengths, Limitations, and Challenges

The strongest feature of the current pipeline is that it now includes a strategy that addresses the root genetic cause rather than only downstream metabolic consequences. In the PEX1 mouse model, base editing corrected the pathogenic allele and improved multiple linked outcomes—metabolites, liver pathology, transcriptomic abnormalities, and growth—while also working in patient cells. Base editing in a ZSD mouse model The field also has increasingly informative natural-history and biomarker studies, which can help identify treatment windows and reduce uncertainty in small clinical trials. Metabolomic biomarkers in ZSD Ophthalmic natural-history study

The limitations are substantial. The current editor targets one mutation and therefore cannot directly treat the many other disease-causing PEX variants. Liver editing does not guarantee sufficient correction in the brain, retina, inner ear, or other affected tissues, and irreversible developmental injury may begin before treatment can be delivered. AAV can trigger immune responses and may be difficult to re-administer, whereas LNP editing will require improved delivery beyond the liver. Small-molecule rescue appears most plausible for residual-function variants and remains preclinical. Base editing in a ZSD mouse model GSNO rescues PEX1G843D models

Outlook and Future Directions

As of October 2, 2026, a cure for Zellweger syndrome is not close enough to predict a clinical timeline, but the field has moved from supportive care alone to a credible genetic-correction strategy for a substantial PEX1 subgroup. The milestones to watch are confirmation of durable safety and benefit in additional animal models, delivery methods that reach brain and retina as well as liver, extension of editing or replacement approaches to other PEX genotypes, and an initial human trial with validated metabolic, liver, developmental, and vision endpoints. Base editing in a ZSD mouse model ZSDvision natural-history study

References

Don't see your disease? Request a report